Gregory Patrick - Supernus Pharmaceuticals CFO, Vice President
| SUPN Stock | USD 28.87 0.13 0.45% |
President
Mr. Gregory S. Patrick, Ph.D. is Chief Financial Officer, Vice President of the Company. Previously, he served as Chief Financial Officer for three privately held life sciences companies R012 Bionor Immuno and Sopherion Therapeutics . From 2001 through 2004, he served as Chief Financial Officer for Medimmune, and from 1999 to 2001, as Chief Financial Officer of Ventiv Health since 2011.
| Age | 66 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Address | 9715 Key West Avenue, Rockville, MD, United States, 20850 |
| Phone | 301 838 2500 |
| Web | https://www.supernus.com |
Supernus Pharmaceuticals Management Efficiency
At this time, Supernus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 19th of April 2024, Return On Capital Employed is likely to grow to 0.01, while Return On Equity is likely to drop 0. At this time, Supernus Pharmaceuticals' Intangibles To Total Assets are very stable compared to the past year. As of the 19th of April 2024, Fixed Asset Turnover is likely to grow to 22.16, while Other Current Assets are likely to drop about 8.5 M. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Janssen | Dynavax Technologies | 70 | |
| Rebecca Peterson | Alkermes Plc | 38 | |
| Michael Landine | Alkermes Plc | 70 | |
| David Johnson | Dynavax Technologies | 56 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Christopher Wright | Ironwood Pharmaceuticals | N/A | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Shane Cooke | Alkermes Plc | 54 | |
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Gordon Pugh | Alkermes Plc | 57 | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| David Gaffin | Alkermes Plc | 52 | |
Management Performance
| Return On Equity | 0.0015 | ||||
| Return On Asset | 0.0056 |
Supernus Pharmaceuticals Leadership Team
Elected by the shareholders, the Supernus Pharmaceuticals' board of directors comprises two types of representatives: Supernus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Supernus. The board's role is to monitor Supernus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Supernus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Supernus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Newhall, Independent Director | ||
| Padmanabh Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property | ||
| James Barrett, Independent Chairman of the Board | ||
| Timothy Dec, Senior CFO | ||
| Tami Martin, VP Affairs | ||
| John Siebert, Independent Director | ||
| Taylor Raiford, Senior Sales | ||
| Georges Gemayel, Independent Director | ||
| Bryan Roecklein, Senior Development | ||
| Jonathan Rubin, VP Officer | ||
| Todd MBA, Senior Access | ||
| MBA MD, Senior Officer | ||
| Frederick Hudson, Independent Director | ||
| Stefan Schwabe, Executive Vice-President - Research & Development, Chief Medical Officer | ||
| Jack Khattar, Founder, CEO and President and Director | ||
| William Nuerge, Independent Director | ||
| Kevin Anderson, Compliance Officer | ||
| RN Esq, Senior Affairs | ||
| Carrolee Barlow, Director | ||
| Frank Mottola, GMP Quality | ||
| Victor Vaughn, Sr. VP of Sales and Marketing | ||
| Michael Barrett, Independent Chairman of the Board | ||
| Gregory Patrick, CFO, Vice President |
Supernus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Supernus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0015 | ||||
| Return On Asset | 0.0056 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 54.73 M | ||||
| Shares Owned By Insiders | 5.11 % | ||||
| Shares Owned By Institutions | 94.89 % | ||||
| Number Of Shares Shorted | 4.82 M | ||||
| Price To Earning | 15.25 X |
Currently Active Assets on Macroaxis
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.